Bound plasmin retained its enzymatic activity, which indicates that its binding does not involve the catalytic active site.
Summary Cells from rat carcinoma cell lines PROb (giving progressive tumours) and REGb (giving regressive tumours) have cell surface receptors which bind specifically rat plasminogen and plasmin. Affinity for Pg was found to be higher in PROb (Kd = 0-7M) than in REGb cells (Kd = 5.10-7M) but with a concomitant decrease in the number of binding sites, 0.9 x 106/cell (range from 0.6 to 1.2 x 106) in PROb vs 3.6 x 106/cell (range 1.2 to 6 x 106 ) in REGb cells. The number and the affinity of binding sites varied in an opposite way in PROb and REGb cells. The difference in affinity parameters was unrelated to the degree of invasiveness of tumour cells in syngenetic rats.
Bound plasmin retained its enzymatic activity, which indicates that its binding does not involve the catalytic active site.
In cell solubilisates plasminogen receptor appeared as one major band situated in the area of 50-60 kDa.
It is now established that proteinases are involved in the invasive process of tumour cells (Mullins & Rohrlich, 1983; Saksela & Rifkin, 1988) . Malignant cells may produce plasminogen activators (PAs) of either the urokinase or tissue type or both. These PAs are able to convert plasminogen into plasmin which is a potent protease (Dano et al., 1985) . Carcinoma cells can use plasmin to activate latent type IV collagenase (Salo et al., 1982) . Plasmin can also take a direct part in the degradation of components of the basement membrane and the surrounding connective tissue, facilitating the migration of tumour cells (Ossowski, 1988) . By using immunofluorescence with antisera against components of the plasmin system on sections of both human colon and breast adenocarcinomas, Burtin et al. (1985; showed that these carcinoma cells had plasminogen or plasmin at their surface, and made the hypothesis that these molecules were bound specifically. Subsequently, Burtin and Fondaneche (1988) demonstrated that cells from human tumour cell line SW 1116 have specific binding sites for plasmin and plasminogen. These binding sites are the same for the proenzyme and the enzyme, but they exhibit a much higher affinity for plasmin than for plasminogen. Recently, analogous results have been obtained in our laboratory on the human MCF7 breast carcinoma cell line (Correc et al., 1990) .
In order to extend this research to animal, we investigated whether rat colonic tumour cells have binding sites for plasminogen. We tested an in vitro system with two sublines of rat colon cancer cells forming either progressive tumours (PROb cells) or regressive tumours (REGb cells).
Materials and methods

Cells
Normal colon was excised from adult healthy WAG rats and carefully washed in 0.9% NaCl. The crypt cells were obtained according to the method of M. Laburthe (personal communication) . Briefly, the washed colon was turned inside out so that the crypt cells were exposed, and washed carefully several times with 0.9% NaCl. Then the epithelial cells were dissociated by using a hypertonic solution containing 1.4% NaCl and 2.5 mM EDTA, collected after gentle centrifugation and resuspended in PBS (phosphate buffered saline).
The tumour cell line DHD/K12 was obtained from a transplantable colon carcinoma induced by 1,2 dimethylhydrazine in BDIX rats (Martin et al., 1983) . Two sublines, named respectively DHD/K12/TR and DHD/K12/TS were selected according to their susceptibility to trypsin-mediated detachment from a plastic surface. Clones derived from these sublines and called DHD/K12/TRb and DHD/K12/TSb were used in this study. When injected into syngenic rats DHD/ K12TRb cells, the most resistant to trypsin-mediated detachment, gave rise to progressive tumours in most of the animals (hence their name of PROb), whereas DHD/K12/TSb cells (named REGb), easily detached by trypsin, gave no tumours or produced tumours which regressed spontaneously in a few weeks (Martin et al., 1983) . These cells were grown in Ham's FIO medium supplemented with 10% foetal calf serum and 1% of antibiotic solution containing 10,000 IU ml-' penicillin and 10,000 UG ml-streptomycin. (Bertrand et al., 1986) . Pg was then labelled with 1251 (Amersham, Les Ulis, France) using the iodogen technique (Fraker & Speck, 1978 (Figure 2 ) and with cold plasmin, but not with high amounts of unrelated cold proteins (Table II) . A strong inhibition was also noted with lysine (50 or 100 mM), proving that Pg interacts with its receptor by the intermediate of lysine-binding sites. Basically, both sublines were able to bind radiolabelled Pg specifically but differences were observed in binding parameters.
In some experiments, the bound radiolabelled Pg was eluted from PROb or REGb cells by using a glycine buffer (pH 3). The major part (from 70 to 90%) of the bound radioactivity could be solubilised, that shows that most of the ligand was not internalised. These eluates were studied by PAGE under reducing conditions followed by autoradiography. A unique Pg band at 92 kD was observed (Figure 3) . The fixation of radiolabelled plasmin on DHD/K12 cells was not studied since it was not possible to activate rat radiolabelled Pg completely with high amounts of human uPA used either soluble or immobilised on CNBR-sepharose column. In fact, we obtained a mixture containing both Pg and plasmin. However experiments with cold plasmin showed that the enzyme inhibited the fixation of labelled Pg on tumour cells at lower doses than the proenzyme. An inhibition of about 50% was obtained with 50-100 nM cold plasmin (Table II) The enzymatic activity of cell-bound Pg or Pli on chromogenic substrate was estimated (Table III) . Similar results were obtained with PROb or REGb cells. Fluorescence intensity was very weak when Pg alone was incubated with tumour cells. It was two to ten fold higher when cells were incubated with increasing doses of plasmin. This activity was always abolished in the presence of aprotinin. Thus, enzymatic activity of plasmin was retained after incubation with the tumour cells and the catalytic active site appeared not to be involved in the binding to cells.
Some experiments were performed on whole cells seeded on glass coverslips. After incubation with a 0.25% trypsin solution, although some cells were detached, the preparations were incubated with biotinylated Pg (usually 12 jg ml' in PBS) for 30 min at 4°C as already described (Correc et al., 1992) . They were reacted with fluoresceinated streptavidin. The ability of tumour cells to bind Pg was not altered since fluorescent patterns were observed on the outlines of remaining cells and on the extracellular matrix, as observed on untraited cells (data not shown).
Characteristics of binding sites on PROb or REGb cells
Radioligand displacement assays by cold Pg performed on PROb cells gave the following results: 65%-80% inhibition in the presence of 1 tLM cold Pg vs 0-10% in the presence of PBS or high amounts of cold ovalbumin or human transferrin. Pg binding was inhibited 50% by 200 nM cold Pg.
Using the data from ten inhibition experiments, the dissociation constant of Pg was calculated according to Scatchard's method. The Kd was about 1.0 x 10-7M. The number of binding sites was 0.9 x 106 per cell (range from 0.6 to 1.2 x 106 per cell).
Analogous experiments were performed with REGb cells (Table II) . Pg binding was inhibited 50% by 1 flM cold Pg.
Using the data from ten inhibition experiments, the dissociation constant was about 5 x 10-7 M. The number of binding sites was about 3.6 x 106 per cell (range from 1.2 to 6.106 by cell). The Figure 4 shows the comparison of the two Scatchard plots obtained respectively with PROb and REGb cells. (Burtin & Fondaneche, 1988; Correc et al., 1990) . It was shown that the same receptors bound human Pli and Pg but the amount needed to inhibit the radiolabelled human Pg binding by 50% was significantly lower for Pli than for Pg. Note that these human receptors linked human Pg with a lower affinity than those detected for rat Pg on PROb or REGb cells (50 fold lower for SW 1116 cells and 10 fold for MCF7 cells).
Another piece of evidence shows that Pli is bound by PROb and REGb cells: the cells incubated with cold rat Pli acquired protease activity. That indicates also that the catalytic active site of Pli is not required for its binding to cancer cells. Furthermore, the rat Pli used to inhibit the binding of radiolabelled Pg was always supplemented with aprotinin which blocks the Pli active site, but does not prevent its competitive effect. Identical results have been previously obtained with human carcinoma cells (Burtin & Fondaneche, 1988; Correc et al., 1990) which suggested that the Pli binding on these rat carcinoma cells was also due to a specific receptor and not to protease-nexin like molecules.
It was not possible to study the receptor for urokinase on PROb and REGb cells, since rat uPA is not available, and it was reported that the receptor for uPA is species-specific (Appella et al., 1987; Estreicher et al., 1989) . However on human carcinoma cell line SW 1116, have shown that receptors for Pli and for uPA are distinct proteins, since a high amount of urokinase does not inhibit the specific binding of plasmin. As we have shown a strong interspecific reactivity between the receptors for Pli and for Pg on human and rat carcinoma cells (Durliat et al., 1991) , it is likely that the two systems are homologous and that rat Pg receptor is distinct from rat uPA receptor.
It is clear that Pg binding sites are surface molecules. Two types of experiments support this conclusion. First, after binding of radiolabelled Pg, acid elution leads to recovery of 70-90% of the bound ligand. Second, fluorescence experiments showed the staining of the surface of whole tumour cells. Note also that on several human tumour cells (SW 1116 and MCF7-MF), Correc et al. (1992) have evidenced images with green fluorescence clearly visible as grains or contours at the surface of these tumour cells. Moreover, Pg binding sites are membrane molecules since dissolved by detergent, but not by hypertonic saline buffer.
Pg binding sites of high capacity, of similar affinities and with common recognition specificities are also reported to be widely distributed on many human blood cells with Kd values of 0.9-1.4I1M (Miles & Plow, 1987) , and on both promyeloid leukaemic U 937 and diploid foetal lung GM 1380 fibroblast cell lines (Plow et al., 1986 reicher et al., 1989) . Thus no significant difference in the specific binding of rat Pg on these two cell lines was detected which might be related to their degree of malignancy. Analyses of solubilisates obtained from both PROb and REGb cells show that these samples contain specific binding sites for radiolabelled rat Pg. In electrophoresis, these receptors exhibited the same mobility than those detected for Pli and Pg on human epithelial tumour cell lines Correc et al., 1990) .
We think that the cell surface Pg binding protein detected in experiments dealing with whole cells corresponds to that found in cell solubilisates. We found only one Pg binding band in Western blots performed with cell solubilisates. This means that this band is similar to the cell surface molecule, unless this latter molecule was denatured during solubilisation process. Other evidence is derived from experiments performed on human MCF7 tumour cells (P. Correc, unpublished results). The Pg receptor was studied by cross-linking technique and solubilisation with SDS. For the complex between Pg and receptor, a molecular weight of 140-150 kDa was obtained after polyacrylamide gel electrophoresis and autoradiography. This indicates a molecular weight of 50-60 kDa for the receptor molecule. As the rat and human receptors are very similar (Durliat et al., 1991) , we believe that the rat Pg receptor has indeed the same molecular weight, similar to that obtained on blotting experiments.
To conclude, this study is the first characterisation of specific Pg binding sites on rat carcinoma cell lines.
